Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | See Remarks | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,683 |
Last balance in matching sequence
After 2026-10-02 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 1 · 2026-10-01 · Exercise / conversion · Acquired 810 · Balance 6,493 F1: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 2 · 2026-10-01 · Sale · Disposed 810 · Balance 5,683 F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction. F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.23 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 3 · 2026-10-02 · Exercise / conversion · Acquired 3,357 · Balance 9,040 F1: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 4 · 2026-10-02 · Exercise / conversion · Acquired 5,833 · Balance 14,873 F1: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 5 · 2026-10-02 · Sale · Disposed 4,446 · Balance 10,427 F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction. F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.23 to $116.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 6 · 2026-10-02 · Sale · Disposed 4,744 · Balance 5,683 F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction. F5: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.25 to $116.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.56 · Expires 2030-02-07 | Direct | 3,357 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 810 · Balance 3,357 F6: Fully exercisable. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.56 · Expires 2030-02-07 | Direct | 0 |
Reported balance
After 2026-10-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-02 · Exercise / conversion · Disposed 3,357 · Balance 0 F6: Fully exercisable. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.26 · Expires 2032-02-02 | Direct | 44,167 |
Reported balance
After 2026-10-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-10-02 · Exercise / conversion · Disposed 5,833 · Balance 44,167 F6: Fully exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction.
F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.23 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.23 to $116.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.25 to $116.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F6: Fully exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2025 Filed Aug 5, 2025 22:47 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 5,823 | $13.56 | $78,959.88 |
DisclosureSEC source: 0000950170-25-103319 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 18, 2025 Filed Jul 21, 2025 23:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 200 | $0.00 Strike: $13.56 | $0.00 |
DisclosureSEC source: 0000950170-25-097371 · ownership.xml · derivative · entry 6 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,394 Underlying: Common Stock · 200 shares Expires 2030-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 18, 2025 Filed Jul 21, 2025 23:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 200 | $73.40 | $14,680.00 |
DisclosureSEC source: 0000950170-25-097371 · ownership.xml · nonDerivative · entry 4 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,066 F2 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction. F1 · balance_after: Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 18, 2025 Filed Jul 21, 2025 23:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 200 | $13.56 | $2,712.00 |
DisclosureSEC source: 0000950170-25-097371 · ownership.xml · nonDerivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 23:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 3,877 | $0.00 Strike: $13.56 | $0.00 |
DisclosureSEC source: 0000950170-25-097371 · ownership.xml · derivative · entry 5 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,594 Underlying: Common Stock · 3,877 shares Expires 2030-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 23:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 3,877 | $73.48 | $284,863.74 |
DisclosureSEC source: 0000950170-25-097371 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,066 F2 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.40 to $73.74 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 23:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 3,877 | $13.56 | $52,572.12 |
DisclosureSEC source: 0000950170-25-097371 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 01, 2025 Filed Jul 4, 2025 00:36 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 100 | $0.00 Strike: $13.56 | $0.00 |
DisclosureSEC source: 0000950170-25-094121 · ownership.xml · derivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,471 Underlying: Common Stock · 100 shares Expires 2030-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 01, 2025 Filed Jul 4, 2025 00:36 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 100 | $73.51 | $7,350.50 |
DisclosureSEC source: 0000950170-25-094121 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,066 F2 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction. F1 · balance_after: Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 01, 2025 Filed Jul 4, 2025 00:36 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 100 | $13.56 | $1,356.00 |
DisclosureSEC source: 0000950170-25-094121 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 00:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 441 | $71.68 | $31,610.88 |
DisclosureSEC source: 0000950170-25-081935 · ownership.xml · nonDerivative · entry 6 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,066 F8 · kind: These shares were withheld by the Issuer in order to satisfy certain withholding obligations in connection with the issuance of share upon the vesting of restricted stock units. F9 · price: The closing price on June 2, 2025 was used to calculate the withholding obligation. F1 · balance_after: Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 5,000 | $0.00 Strike: $13.56 | $0.00 |
DisclosureSEC source: 0000950170-25-081935 · ownership.xml · derivative · entry 7 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,571 Underlying: Common Stock · 5,000 shares Expires 2030-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Fully exercisable. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 749 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-081935 · ownership.xml · nonDerivative · entry 5 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,507 F7 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F1 · balance_after: Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 749 | $71.68 | $53,688.32 |
DisclosureSEC source: 0000950170-25-081935 · ownership.xml · nonDerivative · entry 4 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,758 F5 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 2, 2025. F6 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F1 · balance_after: Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 562 | $78.65 | $44,204.00 |
DisclosureSEC source: 0000950170-25-081935 · ownership.xml · nonDerivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,009 F2 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $78.57 to $78.74 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F1 · balance_after: Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 4,438 | $77.97 | $346,014.44 |
DisclosureSEC source: 0000950170-25-081935 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,751 F2 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $77.56 to $78.55 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F1 · balance_after: Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 5,000 | $13.56 | $67,800.00 |
DisclosureSEC source: 0000950170-25-081935 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 01, 2025 Filed May 6, 2025 00:26 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 9,350 | $0.00 Strike: $13.56 | $0.00 |
DisclosureSEC source: 0000950170-25-063828 · ownership.xml · derivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,571 Underlying: Common Stock · 9,350 shares Expires 2030-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 01, 2025 Filed May 6, 2025 00:26 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 9,350 | $71.96 | $672,781.12 |
DisclosureSEC source: 0000950170-25-063828 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,009 F2 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $71.88 to $72.10 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 01, 2025 Filed May 6, 2025 00:26 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 9,350 | $13.56 | $126,786.00 |
DisclosureSEC source: 0000950170-25-063828 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 00:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 650 | $0.00 Strike: $13.56 | $0.00 |
DisclosureSEC source: 0000950170-25-049813 · ownership.xml · derivative · entry 14 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,921 Underlying: Common Stock · 650 shares Expires 2030-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully exercisable. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 00:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 650 | $114.53 | $74,443.01 |
DisclosureSEC source: 0000950170-25-049813 · ownership.xml · nonDerivative · entry 9 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,009 F2 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction. F6 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.29 to $114.71 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 00:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 650 | $13.56 | $8,814.00 |
DisclosureSEC source: 0000950170-25-049813 · ownership.xml · nonDerivative · entry 8 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $19.26 | $0.00 |
DisclosureSEC source: 0000950170-25-049813 · ownership.xml · derivative · entry 13 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully exercisable. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $15.82 | $0.00 |
DisclosureSEC source: 0000950170-25-049813 · ownership.xml · derivative · entry 12 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2030-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully exercisable. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 75,000 | $0.00 Strike: $16.52 | $0.00 |
DisclosureSEC source: 0000950170-25-049813 · ownership.xml · derivative · entry 11 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully exercisable. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 35,000 | $0.00 Strike: $13.56 | $0.00 |
DisclosureSEC source: 0000950170-25-049813 · ownership.xml · derivative · entry 10 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,571 Underlying: Common Stock · 35,000 shares Expires 2030-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully exercisable. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 5,050 | $102.48 | $517,522.99 |
DisclosureSEC source: 0000950170-25-049813 · ownership.xml · nonDerivative · entry 7 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,009 F2 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction. F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $102.00 to $102.705 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 32,942 | $101.37 | $3,339,416.19 |
DisclosureSEC source: 0000950170-25-049813 · ownership.xml · nonDerivative · entry 6 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,059 F2 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $101.00 to $101.90 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 162,008 | $100.22 | $16,236,571.37 |
DisclosureSEC source: 0000950170-25-049813 · ownership.xml · nonDerivative · entry 5 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,001 F2 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $100.00 to $100.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 50,000 | $19.26 | $963,000.00 |
DisclosureSEC source: 0000950170-25-049813 · ownership.xml · nonDerivative · entry 4 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 40,000 | $15.82 | $632,800.00 |
DisclosureSEC source: 0000950170-25-049813 · ownership.xml · nonDerivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 75,000 | $16.52 | $1,239,000.00 |
DisclosureSEC source: 0000950170-25-049813 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 35,000 | $13.56 | $474,600.00 |
DisclosureSEC source: 0000950170-25-049813 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 22:55 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 421 | $0.00 Strike: $13.56 | $0.00 |
DisclosureSEC source: 0000950170-25-045564 · ownership.xml · derivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,571 Underlying: Common Stock · 421 shares Expires 2030-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 22:55 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 421 | $60.58 | $25,504.18 |
DisclosureSEC source: 0000950170-25-045564 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,009 F2 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction. F1 · balance_after: Includes 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 22:55 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 421 | $13.56 | $5,708.76 |
DisclosureSEC source: 0000950170-25-045564 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 00:58 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 4,579 | $0.00 Strike: $13.56 | $0.00 |
DisclosureSEC source: 0000950170-25-032755 · ownership.xml · derivative · entry 7 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,992 Underlying: Common Stock · 4,579 shares Expires 2030-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Fully exercisable. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 00:58 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 4,579 | $60.69 | $277,901.80 |
DisclosureSEC source: 0000950170-25-032755 · ownership.xml · nonDerivative · entry 5 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,009 F7 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction. F8 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $60.58 to $61.055 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F3 · balance_after: Includes 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 00:58 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 4,579 | $13.56 | $62,091.24 |
DisclosureSEC source: 0000950170-25-032755 · ownership.xml · nonDerivative · entry 4 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: Includes 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 00:58 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 216 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032755 · ownership.xml · nonDerivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,009 F6 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 00:58 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 216 | $59.07 | $12,759.12 |
DisclosureSEC source: 0000950170-25-032755 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,793 F4 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 3, 2025. F5 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 00:58 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 182 | $60.58 | $11,025.56 |
DisclosureSEC source: 0000950170-25-032755 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,577 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F2 · price: The closing price on February 28, 2025 was used to calculate the withholding obligation. F3 · balance_after: Includes 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:58 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 140,000 | $0.00 Strike: $60.58 | $0.00 |
DisclosureSEC source: 0000950170-25-032755 · ownership.xml · derivative · entry 6 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2035-02-28 F9 · derivative.exercise_date: Exercise ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:05 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 3,429 | $0.00 Strike: $13.56 | $0.00 |
DisclosureSEC source: 0000950170-25-014454 · ownership.xml · derivative · entry 5 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,571 Underlying: Common Stock · 3,429 shares Expires 2030-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:05 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 1,571 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0000950170-25-014454 · ownership.xml · derivative · entry 4 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,596 Underlying: Common Stock · 1,571 shares Expires 2029-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:05 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 5,000 | $66.92 | $334,600.00 |
DisclosureSEC source: 0000950170-25-014454 · ownership.xml · nonDerivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,759 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:05 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 3,429 | $13.56 | $46,497.24 |
DisclosureSEC source: 0000950170-25-014454 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:05 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 1,571 | $11.35 | $17,830.85 |
DisclosureSEC source: 0000950170-25-014454 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:24 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 5,000 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0000950170-25-002446 · ownership.xml · derivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,167 Underlying: Common Stock · 5,000 shares Expires 2029-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.